Alexion Pharmaceuticals (ALXN) Downgraded by TheStreet to “C+”

TheStreet cut shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a b- rating to a c+ rating in a research note issued to investors on Friday, November 10th.

Several other equities analysts also recently commented on the company. Zacks Investment Research downgraded Alexion Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, November 1st. Royal Bank Of Canada boosted their target price on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Piper Jaffray Companies reiterated an overweight rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Stifel Nicolaus decreased their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a buy rating on the stock in a research report on Tuesday, October 24th. Finally, SunTrust Banks reiterated a buy rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday, July 14th. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $154.01.

Alexion Pharmaceuticals (ALXN) opened at $107.37 on Friday. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The company has a market capitalization of $24,150.58, a PE ratio of 22.11, a PEG ratio of 1.18 and a beta of 1.22. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same period in the previous year, the business earned $1.23 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. sell-side analysts predict that Alexion Pharmaceuticals will post 4.81 EPS for the current fiscal year.

In other news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Julie O’neill sold 4,375 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total value of $636,300.00. Following the completion of the transaction, the executive vice president now directly owns 26,092 shares in the company, valued at approximately $3,794,820.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,330 shares of company stock worth $774,851. Insiders own 4.35% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Eqis Capital Management Inc. grew its stake in Alexion Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock worth $824,000 after purchasing an additional 38 shares in the last quarter. Rathbone Brothers plc grew its stake in Alexion Pharmaceuticals by 2.5% in the second quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 50 shares in the last quarter. Seven Bridges Advisors LLC grew its stake in Alexion Pharmaceuticals by 2.1% in the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 53 shares in the last quarter. Geneva Advisors LLC grew its stake in Alexion Pharmaceuticals by 0.7% in the second quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock worth $1,388,000 after purchasing an additional 82 shares in the last quarter. Finally, Grandfield & Dodd LLC grew its stake in Alexion Pharmaceuticals by 2.8% in the second quarter. Grandfield & Dodd LLC now owns 3,360 shares of the biopharmaceutical company’s stock worth $409,000 after purchasing an additional 90 shares in the last quarter. 94.15% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals (ALXN) Downgraded by TheStreet to “C+”” was first posted by BBNS and is the sole property of of BBNS. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/alexion-pharmaceuticals-inc-alxn-cut-to-c-at-thestreet/1776058.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.